Loading
A phase 1/2 trial of OPM-101 run by Oncodesign Precision Medicine, not yet recruiting.
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1 is a phase 1/2 interventional study registered as NCT07040436 by Oncodesign Precision Medicine, with 41 participants planned, started 2025-09. Conditions recorded: Advanced Melanoma. Interventions recorded: OPM-101.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/